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Abstract
Background: In proton radiation therapy a constant relative biological effectiveness (RBE) of 1.1 is usually assumed.
However, biological experiments have evidenced RBE dependencies on dose level, proton linear energy transfer
(LET) and tissue type. This work compares the predictions of three of the main radio-biological models proposed
in the literature by Carabe-Fernandez, Wedenberg, Scholz and coworkers.
Methods: Using the chosen models, a spread-out Bragg peak (SOBP) as well as two exemplary clinical cases
(single field and two fields) for cranial proton irradiation, all delivered with state-of-the-art pencil-beam scanning,
have been analyzed in terms of absorbed dose, dose-averaged LET (LETD), RBE-weighted dose (DRBE) and biological
range shift distributions.
Results: In the systematic comparison of RBE predictions by the three models we could show different levels of
agreement depending on (α/β)x and LET values. The SOBP study emphasizes the variation of LETD and RBE not
only as a function of depth but also of lateral distance from the central beam axis. Application to clinical-like
scenario shows consistent discrepancies from the values obtained for a constant RBE of 1.1, when using a variable
RBE scheme for proton irradiation in tissues with low (α/β)x, regardless of the model. Biological range shifts of
0.6– 2.4 mm (for high (α/β)x) and 3.0 – 5.4 mm (for low (α/β)x) were found from the fall-off analysis of individual
profiles of RBE-weighted fraction dose along the beam penetration depth.
Conclusions: Although more experimental evidence is needed to validate the accuracy of the investigated models
and their input parameters, their consistent trend suggests that their main RBE dependencies (dose, LET and (α/β)x)
should be included in treatment planning systems. In particular, our results suggest that simpler models based on
the linear-quadratic formalism and LETD might already be sufficient to reproduce important RBE dependencies for
re-evaluation of plans optimized with the current RBE = 1.1 approximation. This approach would be a first step
forward to consider RBE variations in proton therapy, thus enabling a more robust choice of biological dose
delivery. The latter could in turn impact clinical outcome, especially in terms of reduced toxicities for tumors
adjacent to organs at risk.
Keywords: Proton therapy, Relative biological effectiveness, Monte Carlo, FLUKA
* Correspondence: mairani@cnao.it
Gonzalo Cabal and Kathrin Frey were contributing to this paper during their
past employment at the indicated institution.
†Equal contributors
6Medical Physics Unit, CNAO Foundation, Via Strada Campeggi 53, I-27100
Pavia, Italy
5Heidelberg Ion Beam Therapy Center, Im Neuenheimer Feld 450, D-69120
Heidelberg, Germany
Full list of author information is available at the end of the article
© 2016 Giovannini et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Giovannini et al. Radiation Oncology  (2016) 11:68 
DOI 10.1186/s13014-016-0642-6
Background
Light ion beams exhibit favorable physical characteristics,
which allow for a highly conformal and biologically effect-
ive dose delivery to the tumor, while optimally sparing
adjacent normal tissue. This rationale has boosted their
application in radiation therapy. For clinical patient treat-
ment, a constant relative biological effectiveness (RBE) of
1.1 is currently recommended and applied for proton
beams [1], despite the fact that the RBE of protons de-
pends on many factors such as dose level, linear-energy
transfer (LET), tissue radio-sensitivity, oxygen concentra-
tion and biological end-point [2, 3]. Using a constant RBE
value at each position of a spread-out Bragg peak (SOBP)
of a proton beam and within every tissue is an approxi-
mation, generally supported by the fact that the available
biological data are insufficient to justify clinical usage of
other proposed approaches [4]. In a recent review [3],
Paganetti analysed a large amount of experimental data
available from published literature. His work highlighted
that there is a trend of an increase in RBE as (α/β)x (i.e.,
the ratio between the linear and the quadratic term of the
linear quadratic (LQ) model [5] for the reference photon
radiation) decreases and as the dose decreases. This dose-
effect has been seen especially for systems with low (α/β)x.
Several phenomenological models for RBE predic-
tions have been proposed, for instance by Wilkens and
Oelfke [6], Tilly et al. [7], Carabe-Fernandez et al. [8], and
Wedenberg et al. [9]. Biophysical models are available as
well, such as the microdosimetric-kinetic-model (MKM,
[10]), the local effect model (LEM, [11, 12]), and the
repair-misrepair-fixation (RMF) model [13]. In this work,
the models by Carabe-Fernandez et al., Wedenberg et al.
and a re-implementation of the LEM were chosen for
three main reasons:
 Both biophysical (LEM) and phenomenological
(Carabe-Fernandez et al. and Wedenberg et al.)
models have been taken into account. In
terms of biophysical models, LEM is the model
already used by treatment planning systems
of European dual ion (proton and carbon ion)
therapy facilities for biological optimization in
carbon ion therapy.
 The three selected models assume or predict
different trends of the LET dependence for the β
parameter of the LQ model. For an increasing LET,
β is decreasing according to the implemented
version of the LEM, increasing in Carabe et al.,
and constant in Wedenberg et al.
 Phenomenological models as simple as possible
with no plan-dependent parameters were chosen
to make the comparison more straightforward.
For this reason, the Wilkens and Oelfke model [6]
has been excluded from the analysis.
The increase of RBE with depth of a proton beam
causes a change of the biological beam range. Carabe
and collaborators [4] have quantified the range shift for
a SOBP in water and for a clinical case applying the
Carabe-Fernandez et al. model. They have found that
the shift increases with the physical range but decreases
with increasing dose or (α/β)x.
More recently, Grün and collaborators [14] have stud-
ied the impact of the beam energy, tissue type and dose
level on the biological range of the proton beams by ap-
plying the LEM and performing calculations for SOBPs
in water. They have found that the biological range of
proton beams is strongly dependent on the physical
properties of the beam as well as on absorbed dose and
the biological properties of the irradiated tissue. Exten-
sions in depth of the biologically effective SOBP up to
4 mm (with respect to the value obtained using a constant
RBE of 1.1) have been found.
Treatment planning studies using a variable RBE
scheme have been performed in the past. Tilly and col-
laborators have studied the influence of RBE variations
in a clinical proton treatment for hypopharinx cancer [7]
applying their biological model. They have shown the
importance of considering RBE corrections especially
when organs at risk (OARs) are located immediately
behind the target volume. Carabe and collaborators [15]
have applied their model to study the clinical consequences
of RBE variations in proton therapy of the prostate, brain
and liver. They have found that, for standard fractionated
regimens, RBE values larger than 1.1 were encountered in
prostate and liver tumors as well as the OARs in the brain.
Conversely, RBE values lower than 1.1 have typically been
observed in hypofractionated regimes. Wedenberg and
Toma-Dasu [16] have applied the Wedenberg et al. model
for three brain cases irradiated with proton beams. They
have found that disregarding RBE variations might lead to
suboptimal proton plans (lower biological dose in the tar-
get and higher biological dose in the normal tissues).
In this work, we compare the predictions of three
selected radio-biological models for two tissue specific
parameters characterized by a ratio (α/β)x = 2 Gy and
10 Gy for the photon reference radiation. The (α/β)x
values have been chosen to represent late-responding
tissues (low (α/β)x around 2–3 Gy) and early-responding
normal tissue and most common tumors (high (α/β)x
around 10 Gy). We study in depth the impact of the
different model predictions on RBE, RBE-weighted dose
and biological range for two exemplary clinical cranial
irradiations (single field and two fields configuration)
with state-of-the-art pencil-beam scanning. Moreover, a
SOBP has been simulated in water to study depth- and
lateral- dependent biological quantities for a tissue with
(α/β)x = 2 Gy in a well-controlled scenario without tissue
heterogeneities. The head-to-head comparisons of the
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different RBE models for the same clinical cases allow
assessment of RBE variations and the impact of the
choice of the RBE model, revealing also some common
trends in the predictions of variable RBE schemes in
comparison to the current approximation of a constant
(equal 1.1) RBE. The latter is important to evaluate the
performance of simpler phenomenological models for a
straightforward implementation in treatment planning
systems (TPS), compared to more complex biophysical
models. Moreover, our work highlights the relevance of
LET variations not only along the beam penetration
depth, but also for transversal profiles. Overall, our find-
ings can be used to support decision-making processes in
the clinical practice keeping in mind the uncertainties of
the biological data and the observed spread of model pre-
dictions. In particular, we strongly encourage the next
generation of TPSs to include RBE-based calculations for
proton radiation therapy, even only with the simpler phe-
nomenological models, to enable comparisons between
the standard RBE 1.1 approach and a variable RBE scheme
for improved robustness of the final treatment plan.
Methods
Modeling the biological effectiveness of protons
The Carabe-Fernandez et al. model
The first of the two phenomenological models chosen for
the comparison is the extension by Carabe-Fernandez et
al. [8] of the approach proposed by Dale and Jones [17].
The aim of the approach is to determine, within the LQ
model, relationships between the parameters α and β for
proton radiation and the αx and βx for photon radiation.
Within the LQ framework, considering that a proton
absorbed dose D and a photon dose Dx are isoeffective if:
αDþ βD2 ¼ αxDx þ βxD2x;
Dividing by Dx and considering that RBE =Dx/D by
definition, thus expressing D as Dx/RBE, we arrive at:
αx þ βxDx
 
RBE2−αRBE−β Dx ¼ 0:
Solving for the positive value of RBE:
RBE α; β; αx; βx;Dx
  ¼ αþ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
α2 þ 4βDx αx þ βxDx
 q
2 αx þ βxDx
  :
ð1Þ











RBEmax and RBEmin correspond to the asymptotic
values of the RBE at D = 0 and D =∞, respectively. They
are assumed to contain the dependence of the RBE on
LET. Using Eqs. (1), (2) and (3), an expression for the
RBE that only depends on photon LQ parameters and



























Four sets of experimental data for V79 cells were used
by the authors to assess the dependence of RBEmax and
RBEmin on the dose-averaged LET (LETD). From the linear
regression analysis, the authors calculated intersection
points and slopes of the linear fit. Then, for V79 cells
a (α/β)x value of 2.686 Gy is obtained by averaging
over all the reported experimental values in each data
set. A reciprocal dependence of RBEmax and RBEminon
(α/β)x is assumed. This means that for those tissues with
(α/β)x = 2.686 Gy the slope must be exactly that same one
found fitting V79 cells data, whereas for other tissues the
slope must increase for decreasing (α/β)x and vice versa:
RBEmax LETD; α=βð Þx




RBEmin LETD; α=βð Þx




For the comparison of Carabe-Fernandez model predic-
tions against the other models we have used the unre-
stricted LET in water instead of LETD used in the original
model which means that cells are represented by
water and each particle has the same LET (corre-
sponding to in vitro irradiation with mono-energetic
protons). Equation (4) can be employed in combination
with Eqs. (5) and (6) for studying the RBE of protons in
human tissues, noting that the model has been derived
using V79 cell data. We will refer in the next sections to
the Carabe-Fernandez et al. model as CAR model.
The Wedenberg et al. model
The second considered model has been developed by
Wedenberg et al. [9]. Despite its simple formalism, this
model succeeds in capturing the basic features of RBE
for protons with minimum well validated assumptions.
First, α is assumed to vary linearly with the LET and to
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approach αx when the LET decreases in the LET range
of clinical interest in proton therapy:
α
αx
¼ 1þ k⋅ LET: ð7Þ
Since the ratio α/αx is known to decrease with increas-
ing LET after 30 keV/μm, Eq. (7) is supposed to be valid
for LET lower than this value [9]. Second, since different
values of the α/αx ratio for similar LET values have been
reported in several studies and this is supposed to be
due to the differences between cell lines, an inverse
relationship between the slope k and the tissue response






q is a free parameter which does not depend on the
physical characteristics of the proton beam and on the
biological system. Its value has been determined as
0.434 (Gy μm)/keV fitting the experimental data re-
ported in [9]. In other words, LET variations affect the
survival of low (α/β)x ratio tissues more than high ratio
ones. In the Wedenberg et al. approach, β is assumed to
be LET independent and is merely assumed to be:
β ¼ βx: ð9Þ
If we use the same formalism as introduced for the
Carabe-Fernandez et al. model we obtain for the
Wedenberg et al. model:
RBEmax LET; α=βð Þx
  ¼ 1:00þ 0:434
α=βð Þx
LET; ð10Þ
RBEmin ¼ 1:0: ð11Þ
Each hypothesis of the model has been statistically
tested on the basis of an experimental data set, including
10 different cell lines with (α/β)x values ranging from
2.7 Gy up to more than 70 Gy, irradiated with proton
beams with LET values ranging from 6 keV/μm up to
30 keV/μm. According to the authors, the model is able
to predict the RBE based on the delivered dose, the LET,
and the tissue specific parameter (α/β)x of photons. For
MC-based patient calculations we have applied the
Wedenberg et al. formalism using the LETD instead of
the LET, i. e. taking into account the produced mixed ra-
diation field produced. We will refer in the next sections
to the Wedenberg et al. model as WED model.
The local effect model-version IV
The LEM-version IV developed by GSI Helmholtzzentrum
für Schwerionenforschung [11, 12] relates the biological re-
sponse directly to the double-strand breaks (DSB) pattern.
The main idea is that cell damage depends on the local
DSB density within its nucleus, regardless of the particle
type producing it. In this work the input LEM LQ tables
for protons, which are needed for the calculation, are ob-
tained from a re-implementation of the LEM by our team
[18]. All following references to the ‘LEM’ in this work
refer to this re-implementation of the original LEM model.
As a benchmark and validation of the capabilities of the
LEM re-implementation, comparisons have been made
with experimental data for mono-energetic H and He
beams for the irradiation of different cell lines [18].
The LQ parameters for protons at different energies
are calculated applying the low dose approximation [19],
which describes how to link the input LEM-calculated
intrinsic proton microscopic parameters, αz and βz, to
the macroscopic dose ones, α and β. The parameter
αzfor proton beams at different energies is calculated ap-
plying the HIT LEM re-implementation while βz is calcu-





Dt represents the transition dose at which the survival
curve for photon irradiation is assumed to have an expo-
nential shape with the maximum slope Smax = αx + 2βxDt.
Two different values of Dt have been chosen to assess its
influence (see Table 1). The Dt values used to test the re-
implementation in [18] were low values (≤10.5 Gy); how-
ever we have decided to use a large value of Dt, 40 Gy,
for generating upper limit predictions.
The other LEM input parameters (cell nucleus area
and volume, domain size, etc.) for generating α and β
tables are the same ones as reported in [18]. The α and
β macroscopic parameters of proton beams are used in
the Monte Carlo (MC) code for performing LEM-based
biological calculations, as described in the next section.
Monte Carlo implementation
The MC calculations presented in this work have been
performed using a FLUKA [21, 22]-based MC frame-
work capable to perform calculations on computed tom-
ography (CT) data with a detailed model of ion
irradiation as developed at the Heidelberg Ion Beam
Therapy Center (HIT) [23]. The framework includes the
modeling of the beam line elements and the patient CT
in the FLUKA geometry and a tool for importing the flu-
ences of pencil-like ion beams of different energy and
position, as specified in the treatment plan, and for
Table 1 Photon parameters used for the two representative
tissues for low and high (α/β)x
αx [Gy
-1] βx [Gy
-2] (α/β)x [Gy] Dt [Gy]
0.123 0.0616 2 10; 40
0.616 0.0616 10 10; 40
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simulating their scanned beam delivery [23]. The MC
computational framework has been thoroughly validated
and fine-tuned to reproduce dosimetric measurements
for HIT treatment conditions [23]. Realistic treatment
plans used in this work were prepared at the HIT facility
(Syngo-PT Siemens) and then recalculated with the
FLUKA version 2011.2b.3. LETD, absorbed dose and
RBE/RBE-weighted dose (DRBE) calculations based on
LEM were performed during runtime following the
approach described in [23]. For the biological calcula-
tions applying the WED and the CAR model we have
converted MC-generated LETD maps in RBE/ DRBE dis-
tributions using the expressions previously introduced,
implemented in a post-processing script merging the
several outputs of the parallel MC simulations.
Two brain tumor cases and a SOBP in water have been
simulated. For the SOBP, a single-field irradiation plan op-
timized to achieve a homogeneous three-dimensional dose
distribution of 2 Gy (RBE) (with a constant RBE of 1.1) in
the target region, simulating a 150 mm× 90 mm× 40 mm
tumor centered at 76 mm depth, has been calculated with
the MC. The FLUKA scoring was performed on 1 × 1 ×
1 mm3 voxels. In the first patient case (patient 1) a single
field enters the skull through the parietal bone and the
planning target volume (PTV) is located in the parietal
lobe. The second patient (patient 2) is treated by two fields
entering the temporal bones in opposite directions. The
target volume is located at the base of the skull and several
organs at risk are considered by the dose optimization,
which was performed using the intensity modulation
technique. These cases have been chosen for studying two
different scenarios: single field in a homogenous region
(patient 1) and two fields irradiation of a heterogeneous
region with many critical OARs surrounding the tumor
(patient 2). Both plans include 27 identical dose fractions,
each delivering 2 Gy (RBE) of proton dose to the PTV
assuming a RBE of 1.1. The CT pixel size was 0.65 ×
0.65 mm2 with a fixed slice thickness of 3 mm. MC distri-
butions were calculated by FLUKA on the CT grid.
Evaluation
The predictions of the three models have been studied
by comparing the α and β terms of the LQ model as a
function of LET, and the RBE values as a function of
LET and dose for two tissue types irradiated with proton
beams. Parameters characterizing the hypothetical tissues
considered for our studies are reported in Table 1. An
additional choice of two Dt dose threshold values of 10
and 40 Gy is used. We chose these values for Dt in order
to understand the impact of different Dt on the LEM-
based biological calculations. However, one could also
apply the empirical relationship between (α/β)x and Dt
found by Friedrich et al. [24], as for example performed
in [14].
Two patient plans have been recalculated analyzing
absorbed dose, RBE and DRBE distributions for the three
models and for the two representative tissues for low
and high (α/β)x. Dose-volume histograms (DVH), RBE-
weighted dose-volume histograms (DRBEVH) and dose
averaged LET-volume histograms (LETDVH) have been
studied. The effective range variation due to a variable
RBE scheme has been assessed by looking at the depth
(RRBE x) at which the total DRBE has decreased to a cer-
tain percentage x for all depth profiles sampled in beam-
eye-view along (each) incidence direction of the single
(double) treatment field(s). To account for the fact that
several x values are typically considered by different facil-
ities, the biological range shift is here calculated as the dif-
ference between distal fall-off positions of the physical
dose profile multiplied with 1.1 (RRBE = 1.1) and the DRBE
profile (RvarRBE) in the beam direction for three percentage
x values: 90, 80, and 50 % of the prescribed dose (D):
Rshiftx ¼ RvarRBEx −RRBE¼1:1x : ð13Þ
This approach basically analyzes the location of the
corresponding isodose edge in beam-eye-view, thus
quantifying the critical extension of the high dose region
to the healthy tissue distal to the tumor along each treat-
ment field incidence direction. Resulting two-dimensional
maps of the biological range shift values in beam-eye-view
and histograms on the frequency of a certain range shift
value among all examined beam directions within the
treatment field are evaluated. Profiles that do not reach
the dose levels under study are excluded from the analysis.
In order to rule out a faulty analysis sensitive to MC statis-
tical fluctuations, only profiles with a steep distal fall-off
with a gradient ≤ 30 mm/Gy are considered.
Results
Main model dependencies
Figure 1 shows the comparison between the three
models for the prediction of α (left panels) and β (right
panels) for mono-energetic proton beams as a function
of proton beam LET for two tissues, as reported in
Table 1, with (α/β)x of 2 Gy (upper panels) and 10 Gy
(lower panels). RBE results as a function of proton beam
LET for the two tissues at two photon dose levels of
2 Gy (left column) and of 4 Gy (right column) are
depicted in Fig. 2. Moreover, RBE results at low LET
(1.0 keV/μm) and higher LET (6.5 keV/μm) are pre-
sented as a function of proton dose for the two tissues
in Fig. 3.
SOBP calculations
For comparison of the models in an idealized condition
of a SOBP in water, we have calculated depth- and
lateral-dose, DRBE and RBE profiles applying a tissue
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with (α/β)x = 2 Gy for a SOBP in water. As an example
in the left panels of Fig. 4 dose, LETD, DRBE, and RBE-
depth profiles are shown. In order to assess the variation
of physical and biological quantities as a function of the
lateral distance from the main central axis, DRBE, RBE
and LETD lateral profiles at the middle of the SOBP are
depicted in the right panels of Fig. 4. Calculations per-
formed approximating the mixed radiation field compos-
ition as being constant regardless of the lateral distance
from the central beam axis at each given depth, as ap-
plied in our TPS for carbon ion irradiation, is labeled as
LEM-“TPS”.
Fig. 1 Comparison between three model predictions, as reported in the legends, for α (left column) and β (right column) as a function of LET for
(α/β)x of photons of 2 Gy (upper panels) and 10 Gy (lower panels). For the LEM, predictions for two values of Dt are reported
Fig. 2 Comparison between three model predictions, as reported in the legends, for RBE as a function of LET for (α/β)x of photons of 2 Gy (upper
panels) and 10 Gy (lower panels) at 2(4) Gy reference photon dose as reported in the left (right) column, respectively. For the LEM, predictions for
two values of Dt are reported
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Patient cases calculations
Patient-like treatment cases are summarized in the fol-
lowing. For (α/β)x = 10 Gy the calculations with the CAR
model are not included as outside its limit of applicabil-
ity, as explained in the next section. As an example, in
the left and middle panels of Fig. 5 the proton absorbed
dose (left) and the LETD (right) distributions of the two
patients are depicted. PTV and OAR contours are also
marked by a line. LETDVH for the two patient cases are
shown in the right panels of Fig. 5. RBE distributions
assigning a tissue of (α/β)x = 2 Gy / 10 Gy to the two pa-
tients are shown in Figs. 6 and 7, respectively. The
resulting minimum (minRBE), maximum (maxRBE) and
mean (meanRBE) RBE values in the PTV for the two pa-
tient cases are reported in Table 2. DRBEVH for the PTV
of patient 1 and for the PTV and the brain stem of pa-
tient 2 are shown in Fig. 8. The resulting DRBE,95%,
DRBE,5% and mean (meanDRBE) DRBE values in the PTV
for the two patient cases are summarized in Table 3.
As an example of the carried out biological range ana-
lysis we report in Fig. 9 the biological range shift values
for patient 1 for the (α/β)x = 2 Gy tissue, expressed as
frequency histograms. The resulting mean biological
range shifts for all analyzed scenarios are reported in
Table 4.
Discussion
Basic features of the models
The variations of α and β parameters for proton irradi-
ation were shown as a function of LET for the two sets
of tissue parameters and for the three models (see Fig. 1).
The parameter α increases, as expected, with increasing
LET in the clinically relevant range for protons, accord-
ing to all the three models as shown in the left panels of
Fig. 1. The LEM and the WED models show α to ap-
proach αx at very low LET, whereas the CAR model as-
sumes α/αx = 0.834 for LET→ 0 keV/μm. Nevertheless,
for (α/β)x = 2 Gy all models predict quite similar α values
up to approximately 8 keV/μm. Beyond this value, the
LEM exhibits an enhancement in α, as described also in
[14], that the WED and CAR models do not show. For
(α/β)x = 10 Gy α increases more slowly but, while the
LEM and the WED model show again similar trends,
the CAR model predicts a smaller α, that is lower than
αx for LET values up to approximately 4 keV/μm. It
should be noted that the CAR model has been fitted to
experimental data for V79 cells ((α/β)x ≈ 2.7 Gy) and, as
a result, it is supposed to be more reliable for a low (α/β)x
value than for a high one. No relevant differences for dif-
ferent Dt values are apparent up to 15 keV/μm, for both
tissues. Moreover, as discussed in [14], the LEM predicts a
vanishing slope for the RBE-LET dependence in the limit
of LET→ 0 keV/μm, as shown in Fig. 2 of this work.
Trends of the β parameter are quite different for the
three models (see right panels in Fig. 1). The CAR model
predicts β to slowly increase as the LET increases, with
a slope that decreases with increasing (α/β)x ratio. Ac-
cording to the WED model the parameter β is constant
and equal to βx, whereas in the LEM framework β
decreases with increasing LET for the applied LEM
Fig. 3 Comparison between three model predictions, as reported in the legends, for RBE as a function of proton dose for (α/β)x of photons of
2 Gy (upper panels) and 10 Gy (lower panels) at 1(6.5) keV/μm as reported in the left (right) column, respectively. For the LEM, predictions for two
values of Dt are reported
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implementation. An improved description of the β term
within the LEM framework can be found in [12]. More-
over, while the LEM predicts β to approach βx for very
low LET values, the CAR model assumes β/βx = 1.09 for
LET→ 0 keV/μm. Understandably, variations of Dt affect
much more β than α and are more noticeable for high
LET values, since Dt is expected to become more im-
portant with increasing dose.
Figure 2 shows RBE predictions as a function of the
LET for the two considered tissues at two different pho-
ton dose levels: 2 and 4 Gy. As expected, the RBE
increases for increasing LET in the LET range analyzed,
decreases for increasing dose, and increases for decreasing
(α/β)x of the tissue.
Despite different trends found for β in case of (α/β)x =
2 Gy (see upper panels in Fig. 2), the three models pre-
dict similar RBE values for LET values up to 8 keV/μm
for both dose values (mainly due to compensation effects
between α and β), whereas beyond 8–10 keV/μm the
LEM shows a RBE prediction higher than the other
models (due to the enhancement of α). The RBE is equal
to 1.1 approximately at 2.5 keV/μm for the LEM and
between 1 and 1.5 keV/μm for the other models at a
dose level of 2 Gy. However, at a dose level of 4 Gy, the
RBE reaches the value of 1.1 approximately at 4 keV/μm
according to the LEM, at 1 keV/μm for the CAR model,
and at 2 keV/μm for the WED model. According to the
CAR model, at Dx = 4 Gy the RBE does not approach
unity for very low LET values due to the parameter β be-
ing higher than βx in the low LET region (and becoming
more important at higher doses). For (α/β)x = 10 Gy, as
shown in the lower panels in Fig. 2, the LEM and the
WED model show a similar trend to each other, while
the CAR model predicts the RBE to be smaller than one
for low LET values. This is a consequence of α being
lower than αx in the low LET region. The effect is re-
duced at Dx = 4 Gy because of the reduced importance
of α. The RBE is equal to 1.1 approximately at 3 keV/μm
Fig. 4 Left: DRBE and RBE profiles as function of depth calculated with the three biological models for the (α/β)x = 2 Gy tissue and assuming an
RBE of 1.1 are depicted. Dose and LETD values are also shown in the upper panel. Right: lateral DRBE and RBE profiles in the middle of the SOBP
for the three biological models for the (α/β)x = 2 Gy tissue are shown together with RBE = 1.1 assumption. LETD values are also shown in the
upper panel
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for the WED model, at 4.5 keV/μm for the LEM, and at
6 keV/μm for the CAR model at a dose level of 2 Gy.
Conversely, at a dose level of 4 Gy, the RBE achieves the
value of 1.1 approximately at 4 keV/μm according to the
WED model, at 5 keV/μm for the LEM, and at 6 keV/μm
for the CAR model. The RBE predictions by the LEM
model when varying Dt differ beyond approximately
5 keV/μm. The difference increases as LET and dose
increase.
Figure 3 shows predictions of RBE as a function of the
proton dose by the three models for low LET (1 keV/μm)
and high LET (6.5 keV/μm). The LEM and the WED
model exhibit similar trends. The RBE increases with de-
creasing dose with only an exception at low LET and high
(α/β)x ratio. For (α/β)x = 2 Gy (upper panels in Fig. 3), and
low LET, according to the LEM, the RBE is between 1 and
1.1 at any dose level, whereas it is higher than 1.1 for dose
values smaller than ≈ 1.2 Gy according to the WED model.
At high LET, the RBE is higher than 1.1 in the studied
dose range for all the three models, and reaches values
between 2 and 2.3 at very low dose values. For (α/β)x =
10 Gy (bottom panels in Fig. 3), at low LET, the RBE
increases slightly with decreasing dose according to the
WED model, whereas it is almost constant in the studied
dose range according to the LEM. At high LET, the RBE is
higher than 1.1 in the whole dose range and reaches
values between 1.2 and 1.3 at very low doses. Variations in
the RBE predictions by the LEM when changing Dt are
apparent only for high LET and at high dose. The CAR
model predicts that for high LET the RBE decreases as the
dose increases for (α/β)x = 2 Gy while for (α/β)x = 10 Gy it
remains nearly constant. Moreover, the CAR model pre-
dicts the RBE to increase with increasing dose, at least for
low LET and in particular for (α/β)x = 10 Gy. This is due
to the fact that RBEmax can be lower than RBEmin under
certain conditions. In fact, expressing Eq. (4) as a function





























Fig. 5 Absorbed dose to water (left) and LETD (middle) distributions for the two patient cases (top: patient 1, bottom: patient 2) are depicted. PTV
and OAR contours are also outlined. LETDVH are shown in the right panels
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its derivative1 with respect to the proton dose results to















If Eq. (14) is not fulfilled the CAR model should be
considered inapplicable. As a consequence, for the tis-
sues studied in this work, the CAR model can only be
considered applicable if:
LET > 1:24 keV=μm½  for α=βð Þx ¼ 2Gy ; ð15Þ
LET > 6:20 keV=μm½  for α=βð Þx ¼ 10Gy : ð16Þ
For this reason, the CAR model has not been taken
into account for the considered clinical investigations with
(α/β)x = 10 Gy. However, the results presented in [25] sug-
gest that the condition RBEmax > RBEmin could, in certain
cases, not be fulfilled, i.e., RBE at low doses of low LET
particles (e.g., low LET carbon ions in the Karger and col-
laborators’ paper) is lower than the RBE for high doses of
the same particles with the same LET. Additional experi-
mental investigations are needed for further understand-
ing this scenario and in general the capabilities and the
limits of the models analyzed.
Model dependencies in a SOBP
DRBE and RBE profiles as function of depth calculated
with the three biological models for the (α/β)x = 2 Gy
Fig. 6 RBE distributions for patient 1 (upper panels) and patient 2 (lower panels) are shown for (α/β)x = 2 Gy and variable RBE applying the three
biological models (left: LEM, middle: Carabe, right: Wedenberg). PTV and OAR contours are depicted with lines
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Fig. 7 RBE distributions for patient 1 (upper panels) and patient 2 (lower panels) are shown for (α/β)x = 10 Gy and variable RBE applying the two
biological models (left: LEM, right: Wedenberg). PTV and OAR contours are depicted with lines. The Carabe model is not considered as being
outside its range of reliability (cf. Eqs. 14 and 16)
Table 2 Minimum (minRBE), maximum (maxRBE) and mean (meanRBE) RBE values in the PTV for the two patient cases for (α/β)x = 2 Gy
and 10 Gy
(α/β)x = 2 Gy (α/β)x = 10 Gy
Patient Model minRBE maxRBE meanRBE minRBE maxRBE meanRBE
1 LEM
Dt = 10 Gy
1.10 1.70 1.19 1.05 1.34 1.09
2 1.17 1.41 1.22 1.05 1.19 1.10
1 LEM
Dt = 40 Gy
1.15 1.90 1.27 1.05 1.45 1.12
2 1.22 1.57 1.30 1.09 1.26 1.13
1 WED 1.20 1.64 1.24 1.10 1.26 1.11
2 1.22 1.42 1.27 1.10 1.19 1.12
1 CAR 1.20 1.60 1.27
2 1.23 1.43 1.28
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Fig. 8 DRBEVHs for PTV of patient 1 for (α/β)x = 2(10) Gy are depicted in left (right) upper panels for a fixed RBE of 1.1 and variable RBE applying
the three (two) biological models. DRBEVHs for PTV and brain stem of patient 2 for (α/β)x = 2(10) Gy are depicted in left (right) bottom panels for a
fixed RBE of 1.1 and variable RBE applying the three (two) biological models
Table 3 DRBE,95 %, DRBE,5 % and mean (meanDRBE) DRBE values expressed in Gy (RBE) in the PTV for the two patient cases for (α/β)x = 2 Gy
and 10 Gy
(α/β)x = 2 Gy α/β)x = 10 Gy
Patient Model DRBE,95 % DRBE,5 % meanDRBE DRBE,95 % DRBE,5 % meanDRBE
1 RBE = 1.1 1.94 2.19 2.07 1.94 2.19 2.07
2 1.86 2.18 2.04 1.86 2.18 2.04
1 LEM
Dt = 10 Gy
2.04 2.50 2.23 1.88 2.20 2.03
2 2.03 2.45 2.26 1.83 2.19 2.03
1 LEM
Dt = 40 Gy
2.14 2.71 2.38 1.92 2.29 2.09
2 2.16 2.65 2.41 1.89 2.28 2.10
1 WED 2.17 2.54 2.35 1.95 2.23 2.08
2 2.15 2.53 2.36 1.89 2.23 2.08
1 CAR 2.19 2.57 2.37
2 2.16 2.57 2.38
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tissue and assuming an RBE of 1.1 are depicted in Fig. 4
(left panels) together with the dose and LETD values
(upper-left panel).
The CAR and WED models produce similar DRBE
values always higher than the clinically assumed one
(with a RBE of 1.1). The CAR/WED RBE values in the
entrance and in the middle of the SOBP are, respect-
ively, 1.15/1.18 and 1.27/1.26. The LEM DRBE prediction
assuming Dt = 10 Gy is close to the DRBE values with
RBE = 1.1 in the entrance channel, while it increases as
function of depth in the high dose region of the SOBP,
eventually exceeding the CAR and the WED predictions
in the last millimeter of the SOBP. Applying higher Dt
values produces an enhancement of the DRBE at the
depths with higher LETD values. LEM RBE values in the
entrance and in the middle of the SOBP are respectively,
1.07/1.1 and 1.21/1.29 for Dt = 10 Gy / 40 Gy.
Lateral DRBE and RBE profiles in the middle of the
SOBP for the three biological models for the (α/β)x = 2 Gy
tissue are depicted in the right panels of Fig. 4, together
with the LETD values.
Analyzing the lateral DRBE profiles in terms of 80 – 20 %
fall-off we have found the following values: 13.3 mm with
RBE 1.1, 13.9 mm for LEM-“TPS” approximation,
14.0 mm for the WED model, 13.9 mm for the CAR
model and 14.1/14.7 for the LEM with Dt = 10 Gy / 40 Gy.
Hence, a widening of the field in terms of DRBE of roughly
1.0 mm in comparison to assuming a constant RBE of 1.1
has been found independent of the model used (CAR/
WED/LEM). Properly taking into account the variation of
the mixed radiation field (secondary charged particles
produced in nuclear reactions) not only as a function of
depth, but also laterally, results in an increase of the RBE
in the low dose region (comparing LEM and LEM-“TPS”
like predictions) and an increase in the lateral fall-off of
about 0.2 mm. This region corresponds to higher LETD
values compared to the central part of the field, due to the
primary protons and the secondary higher LET particles
stopping.
Model dependencies in patient cases
The aim of proton treatment planning is to deliver a
dose as uniform as possible to the target, sparing healthy
tissues (see Fig. 5). Uniform dose distributions do not
ensure a homogeneous LETD distribution. Moreover, equi-
valent dose distributions do not necessarily correspond to
Fig. 9 Histograms for biological range shift values for (α/β)x = 2 Gy and patient 1, taking into account profiles exhibiting a gradient≤ 30 mm/Gy:
90 % Dpresc level in the left panel, 80 % Dpresc level in the middle panel and 50 % Dpresc level in the right panel
Table 4 Mean biological range shifts in mm for the two patient cases for (α/β)x = 2 Gy and 10 Gy as deduced from the beam-eye-view
range shift maps
(α/β)x = 2 Gy (α/β)x = 10 Gy
Patient Model 90 % Dpresc 80 % Dpresc 50 % Dpresc 90 % Dpresc 80 % Dpresc 50 % Dpresc
1 LEM
Dt = 10 Gy
3.74 4.33 4.07 1.73 1.81 1.64
2 3.15 2.99 3.55 0.57 0.45 0.66
1 LEM
Dt = 40 Gy
4.75 5.42 4.97 2.30 2.44 2.10
2 4.50 4.41 4.84 1.34 1.11 1.22
1 WED 3.16 3.64 3.39 1.11 1.16 1.03
2 3.64 3.60 4.15 0.76 0.64 0.74
1 CAR 3.10 3.51 3.17
2 3.55 3.37 3.58
Unreliable shallow profiles (>30 mm /Gy) have been excluded. Three percentage values of the prescription dose have been considered
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equivalent LETD distributions. High LETD regions can be
distributed in a complex way in a patient geometry, espe-
cially if more than one field is applied. Representative slices
of LETD distributions and the LETDVH of the two patients
are shown in Fig. 5.
For patient 1, there is a region of intermediate LETD
values (2.5–5 keV/μm), covering almost the whole PTV
(95 %) and in the remaining volume values up to
8.1 keV/μm are observed. In the region posterior to the
target (with respect to the beam direction) the LETD is
between 8 and 12 keV/μm.
For patient 2, LETD is between 3 and 4.5 keV/μm in
almost the entire PTV (95 %), and it is up to 6.5 keV/
μm in the remaining volume. For optic chiasma and
nerves, which are partially included in the PTV, LETD
values do not exceed 5 keV/μm. Higher LETD spots are
located in tissues surrounding the PTV, e.g., 5 % of the
brain stem volume exhibits LETD values beyond 5 keV/
μm and a maximum LETD of 7.4 keV/μm. LETD values
found in this study are consistent with the values found
in [26].
Taking into account LETD conditions on the LET
values for the CAR model reported above, one can con-
clude that the CAR approach can be applied for RBE/DRBE
calculations only for (α/β)x = 2 Gy in our case.
In Figs. 6 and 7, RBE distributions obtained from the
three (two) models for (α/β)x = 2(10) Gy are shown,
respectively, for the two patients.
For patient 1, the three models predict the RBE to be
between 1.1(1.05) and 1.9(1.5) in the PTV for (α/β)x =
2(10) Gy, respectively (see Table 2).
For patient 2, the three models predict the RBE to be
between 1.2 and 1.6 in the PTV (see Table 2). High RBE
spots correspond, as expected, to high LETD values. For
(α/β)x = 10 Gy, the RBE varies more slowly with increas-
ing LET. These results are in line with the values found
in a previous publication [7]. There, the authors found
RBE values between 1.1 and 1.2 within the clinical target
volume in a multiple field hypopharinx case ((α/β)x ≈
10 Gy) and higher values in the spinal cord ((α/β)x ≈
2 Gy). Moreover, our results are in agreement with
values found by Gerweck and Kozin in [27] for (α/β)x ≈
7–13 Gy in cell survival experiments.
Representative DRBEVHs are shown in Fig. 8 for the
two patient cases. For patient 1 in case of (α/β)x = 2 Gy,
when applying RBE = 1.1, a DRBE between 1.9 and 2.2 Gy
(RBE) is obtained in the PTV. Conversely, applying the
three models yields DRBE values between 2.0 and 2.7 Gy
(RBE) (see Table 3). CAR, WED and LEM with Dt =
40 Gy give similar meanDRBE values, while LEM with
Dt = 10 Gy estimates an about 6 % lower meanDRBE
value inside the PTV.
DRBE predictions for patient 1 for (α/β)x = 10 Gy by all
the models are consistent (within about 3 % looking at
meanDRBE) and similar to the DRBE obtained with a fixed
RBE of 1.1. Applying the LEM with Dt = 10 Gy or 40 Gy
seems to have a low impact on DRBEVH PTV for (α/β)x =
10 Gy (see Table 3).
For patient 2, larger variations between fixed and vari-
able DRBE have been found for (α/β)x = 2 Gy with respect
to (α/β)x = 10 Gy, especially within the PTV. The PTV
exhibits DRBE values between 1.9 and 2.2 Gy (RBE) for
RBE = 1.1 and between 2.0 and 2.7 Gy (RBE) for variable
RBE, in the case of (α/β)x = 2 Gy (see Table 3). For the
brain stem, with the (α/β)x = 2 Gy tissue, the DRBE,5%
values range from 0.9 Gy (RBE) applying RBE = 1.1 up to
1.2 Gy (RBE) for variable RBE.
In summary, DRBE predictions by the three considered
models are often higher than the values used in clinics
with a fixed RBE of 1.1, especially for high LETD areas
and low (α/β)x ratios. Variations exceeding 10 % of the
prescription dose were found within the PTV. Since 5 %
dose variations can produce 10–20 % variations in tumor
control probability and 20–30 % variations in normal tis-
sues complication probability [28], differences found in
this study can be clinically significant. However, it should
be kept in mind that lower RBE values are typically found
in vivo compared to the in vitro ones, which are inherently
affecting our model calculations.
It is interesting to notice that similar variations were
also observed when using the more recent model of
McNamara et al. [29], which draws on very similar
assumptions as the WED model for the α term, but
on a more recent re-evaluation of in-vitro proton experi-
ments reported in [3]. In this case, agreement within
about 6 % in terms of mean DRBE in the PTV was ob-
served with the other LETD-based models.
In terms of range variations, Fig. 9 shows, as an
example, biological range shift values reported as histo-
grams for patient 1, when using the (α/β)x = 2 Gy tissue.
Mean biological range shifts for the two patients and the
two tissues are reported in Table 4. Carabe and collabo-
rators found similar range shift values (2–3 mm) for a
(α/β)x approximately equal to 2 Gy, applying the CAR
model to a patient case [4]. Moreover, increasing the Dt
value for LEM produces on average larger biological
range shifts. All presented results suggest caution in pro-
ton therapy treatment planning, especially if OARs are
close to the target. Usually, safety margins are applied to
take into account range uncertainties and to ensure the
target dose coverage.
The observed findings suggest that, regardless of the
used biological model, a biological range shift margin of
few millimeters distal to the target volume (with respect
to the chosen beam direction) should be taken into
account when designing the treatment [30]. Since safety
margins are calculated with different procedures at each
facility [31], findings comparing the outcome of different
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models, as performed in this study, may help developing
some general recommendations for medical physicists
during treatment planning. For example, opposite beams
arrangements, when clinically available, should be pre-
ferred to single field/orthogonal ones to reduce the
resulting LETD and RBE values, as shown comparing the
patient cases in this work. Moreover, active beam scan-
ning techniques should be further exploited to push
LETD areas away from OARs, while preserving dose
coverage in the PTV. The PTV definition should take
into account biological range uncertainties. In addition
to obvious depth dependences of LET variations, also
lateral variations due to scattering effects should not be
neglected and could become important at the tumor
edges, as more clearly shown by the SOBP study in water
(Fig. 4 - right panel).
Conclusions
Despite using models with quite different assumptions,
the observed results show largely consistent deviations
to the current practice of proton therapy biological plan-
ning with a constant RBE of 1.1. These findings suggest
that it is worth considering at least main RBE dependen-
cies (dose, LET and (α/β)x) in treatment planning, espe-
cially if beams point toward or pass laterally adjacent to
OARs, and being particularly cautious for tissues with a
low (α/β)x ratio. Hence, it is strongly advisable to have
computational tools which can model such variable RBE
(maybe even using simpler phenomenological models
such as the WED model or the more recent McNamara et
al. model) and use those variations as general guidance in
taking biological uncertainties into account. Future work
should indeed provide better experimental insights to en-
able identification of the model of choice, including a
comparison to more recent and not yet thoroughly exam-
ined models such as the McNamara et al., the RMF and
the MKM models, and the underlying optimal parameters
for eventual clinical deployment towards direct planning,
besides the suggested usage for robustness assessment.
Endnotes
1The derivative can be performed with the tools avail-
able on-line such as Wolfram|Alpha.
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